Articles tagged with Cancer Cells
Joanna Wardwell-Ozgo, a Kennesaw State assistant professor, received a $720,000 NIH grant to investigate the hormonal control of cancer. She aims to understand how hormones affect cellular growth and development, with potential implications for disease mechanisms.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
A team at Lund University has discovered a surface protein, SLAMF6, that helps leukemia cells evade the immune system. The researchers developed an antibody to block this mechanism, restoring the immune system's ability to kill cancer cells in laboratory trials and mice.
Researchers at Johns Hopkins University discovered a novel way to boost the natural immune system, which prevents cancer recurrence and improves survival rates. The study used immune-activating agents to stimulate killer T cells and induce the formation of tumor-specific IgG antibodies.
Scientists have created a high-potency IRE1 inhibitor with a unique inhibition mode that targets the unfolded protein response in cancer cells. This compound binds to the kinase pocket of IRE1, allosterically suppressing its RNAse activity and restoring proper protein folding.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
A joint team from The University of Osaka revealed that soft particles exhibit unique focusing patterns compared to rigid particles, influencing their focusing behavior. The study provides fundamental insights into the underlying physics, offering a new theoretical model explaining particle behavior under various flow regimes.
Researchers have discovered how Fusobacterium nucleatum binds to human cell receptors CEACAM1 and CEACAM5, which are frequently overexpressed on many types of cancer cells. This binding mechanism is crucial for developing novel antitumor therapies.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
Researchers found that glioblastoma cells in clusters are less deadly than those that disperse from these clusters. The dispersed cells are more plastic and resistant to therapy, making them a major contributor to treatment resistance and poor patient outcomes.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
Scientists used long-read whole-genome sequencing to analyze methylation patterns in urine DNA, identifying bladder cancer. The approach outperformed existing tests in detecting cancer even at low tumour DNA levels.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A team of Japanese researchers has identified shootin1b as a protein that promotes cell migration in glioblastoma, the most common and difficult-to-treat brain tumor. By suppressing abnormal activity of shootin1b, the study suggests a potential target for preventing glioblastoma spread.
A new computational tool called scODIN simplifies single-cell analysis by automating cell type identification in scRNA-seq data. It allows users to define specific cell subsets at different levels of detail and recognizes cells with intermediate phenotypes or transitional states, capturing complexity missed by traditional methods.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
A new study from Mizzou's College of Veterinary Medicine analyzed the effects of radioactive iodine therapy on thyroid cancer in dogs. The research found that tailoring the dose of radiation more precisely for each dog could improve outcomes and potentially lead to more targeted care.
A new study demonstrates the safety and potential benefits of a perioperative combination immune checkpoint blockade in resectable mesothelioma. Patients treated with the regimen lived a median of 28.6 months, with nearly 36% alive and recurrence-free at follow-up.
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
Researchers at SMART Alliance for Research and Technology developed a powerful tool to scan thousands of biological samples and detect transfer ribonucleic acid (tRNA) modifications, which help control cell growth and response to diseases. The tool opens up new possibilities for disease research, diagnostics, and treatment development.
Scientists have found a way to stop brain cancer cells from spreading by 'freezing' hyaluronic acid molecules in place. This approach could lead to a new type of treatment for glioblastoma, the most aggressive form of brain cancer.
Researchers discovered that disrupting protein quality control slows tumor growth in rhabdomyosarcoma, a rare and aggressive cancer primarily affecting children. The treatment, which targets the proteostasis network, significantly slowed or stopped tumor growth in mice implanted with human RMS tumors.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
A new study reveals that body cells change their shape to close gaps such as wounds, using a combination of crawling movements and 'purse-string' contractions. The researchers discovered that the endoplasmic reticulum's ability to reorganize in response to edge curvature plays a crucial role in epithelial cell movement.
The ARCHER study aims to determine whether ultra-hypofractionated stereotactic body radiation therapy is non-inferior to hypofractionated radiotherapy in preserving bladder function. Patients will be randomly assigned to receive either 4 weeks of daily or 5 days of ultra-hypofractionated SBRT.
A team of researchers developed a technology that allows them to measure millions of cell-to-cell interactions quickly and affordably. The study shows that this approach can help predict how patients will respond to immunotherapies, laying the foundation for more personalized treatments.
Researchers developed a software fueled by genomics to predict cancer cell behavior, combining genomics technologies with computational modeling. The new 'grammar' enables communication between biology and code, allowing scientists to build digital representations of multicellular biological systems and simulate diseases like cancer.
Research at University of Arizona Health Sciences found PFAS exposure affects gene activity, tied to cancers, neurological disorders, and autoimmune conditions. Changes in miRNA activity indicate potential health risks, suggesting a link between environmental exposures and disease.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
Researchers found that radiation plus immunotherapy induces a systemic anti-tumor immune response in non-small cell lung cancer, even in tumors that do not typically respond to immunotherapy. The combination therapy improved clinical response in patients whose tumors harbor features of immunotherapy resistance.
Scientists developed a material that can stick to tumors, pumping out chemotherapy drugs for days, minimizing impact on healthy tissue. Early results show great promise for reducing clinical treatments and improving patient outcomes.
A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
Researchers developed OmicsTweezer, a tool that uses machine learning and single-cell data integration to analyze human tissue. The tool can estimate cell type composition in tumors and surrounding tissues, which could help pinpoint potential therapeutic targets.
Researchers at Emory University have discovered that psilocybin can delay cellular aging by over 50% and extend the lifespan of human skin and lung cells. In a study involving aged mice, psilocybin was shown to increase survival by 30% and improve physical features, suggesting potential for anti-aging therapies.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.
A novel fluorescent probe, SLY, has been developed to precisely identify hepatocellular carcinoma tissue using sialylated glycans on the cell surface. The probe outperforms conventional methods by clearly distinguishing tumor margins within liver tissues.
A study by Arc Institute and Stanford University scientists reveals that the target site of a popular STING inhibitor lacks a pocket found in mouse STING, making it challenging to develop effective human treatments. The research proposes targeting STING by preventing oligomerization, a key checkpoint prior to activation.
Researchers have identified a single genetic difference in Fas Ligand, an immune protein, that makes it vulnerable to being disabled by plasmin, a tumor-associated enzyme. This vulnerability seems unique to humans and may contribute to the effectiveness of certain cancer treatments.
Scientists at Nagoya University discovered that dying cancer cells can trigger an inflammatory feedback loop that promotes tumor growth. When macrophages consume dying cancer cells, they produce cytokines that activate growth signals in remaining cancer cells.
Researchers developed an AI tool called AAnet to characterize cancer cell diversity, identifying five distinct cell groups with different gene expression profiles. This could lead to more targeted therapies and improved patient outcomes.
Researchers from Université Libre de Bruxelles discovered inflammation-induced cellular reprogramming leading to tumor initiation. They found that this process occurs differently in various regions of the prostate, with severe cases associated with more aggressive cancers.
Researchers discovered dynamic cells coordinate movements to sculpt living tissue in developing fruit flies, highlighting a powerful role of migrating cells in organ formation. This finding suggests similar systems may shape different organs, including the brain and testis.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
A pilot study found that exercising during chemotherapy can increase the number of immune cells fighting cancer, including CD8+ T cells and natural killer cells. The exercise programme improved patients' aerobic fitness, leading to stronger immune responses inside tumours.
Researchers identified a novel region in AR that binds to PCNA, and developed a small peptide to mimic this region, blocking the AR-PCNA connection. This approach reduced cancer cell growth, particularly in patients with limited treatment options.
Researchers at Ben-Gurion University of the Negev have made a breakthrough in harnessing patient's own T-cells to fight off cancer by creating artificial surfaces mimicking natural immune cells. These surfaces, engineered with nanostructures, strengthen and prolong activation of T-cells, leading to more effective immunotherapy.
Cancer cells and immune cells without the Y chromosome tend to have poorer outcomes, making them more aggressive. Researchers hope to adapt therapies to account for this loss to improve treatment effectiveness.
Researchers discovered a specialized histone arrangement, called the CENP-A–H4 octasome, in centromeric regions. This unique structure likely contributes to proper kinetochore formation and mitosis.
Researchers developed a 3D in vitro culture system to study tumor cell behavior, finding that clusters can infiltrate blood vessels by disrupting the endothelial barrier. This discovery suggests new targets for cancer treatment strategies.
A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...
Researchers developed an artificial intelligence technique that detects DNA fragments in patient blood to monitor treatment response. The ARTEMIS-DELFI approach was found to be more effective and simpler than existing methods, allowing for quicker identification of patients who are not responding to therapy.
Researchers at MIT developed a method to quickly measure cell density, which can predict whether immunotherapies will work in patients or how tumors will respond to drug treatment. The technique uses a combined microfluidic device and fluorescent microscope to measure up to 30,000 cells in an hour.
Dr. Britta Will has been appointed as the permanent director of the Ruth L. and David S. Gottesman Institute, succeeding Ulrich Steidl. Her research focuses on restoring blood regeneration in older adults and those with cancer. She aims to advance fundamental research into stem cell function and tissue regeneration to combat chronic de...
A study led by Johns Hopkins Medicine scientists found that rearranged genes in a rare type of kidney cancer form liquid droplets that turn on cancer-promoting genes. By disrupting these droplets, researchers may develop new therapies for this currently untreatable cancer.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
Researchers developed a comprehensive cell line atlas to better understand the biology of advanced biliary tract cancer. The atlas identifies new molecular subtypes and therapeutic targets, offering a path toward more tailored treatment strategies.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.